Patent: 9,872,854
✉ Email this page to a colleague
Summary for Patent: 9,872,854
Title: | Methods for the treatment of psoriatic arthritis using apremilast |
Abstract: | Methods of treating, managing or preventing psoriatic arthritis are disclosed. Specific methods encompass the administration of apremilast, alone or in combination with a second active agent. |
Inventor(s): | Day; Robert (Newtown, PA) |
Assignee: | Celgene Corporation (Summit, NJ) |
Application Number: | 14/209,874 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,872,854 |
Patent Claims: | see list of patent claims |
Details for Patent 9,872,854
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2033-03-14 |
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2033-03-14 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2033-03-14 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2033-03-14 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2033-03-14 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 02/01/2007 | ⤷ Try a Trial | 2033-03-14 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |